Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Cardiovascular outcomes

- PMLiVE

Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

Novartis will gain cardiovascular treatment option pacibekitug

- PMLiVE

Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition

The deal includes a candidate in phase 3 development to prevent complications of atrial fibrillation

- PMLiVE

Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn

The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

- PMLiVE

Getting to the Heart of the Matter: Medscape Education at AHA 2024!

Come join Medscape Education at the American Heart Association (AHA) 2024 Scientific Sessions in Chicago, IL, from November 16-18 — a dynamic event packed with cutting-edge cardiology education that you...

Medscape Education

- PMLiVE

Medscape Education Wins Best Practice Award for Learner Outcomes at NAMEC

This year's winners have been announced  for the National Association of Medical Education Companies (NAMEC) awards. These awards recognize best practices-ideas or processes that can be implemented by NAMEC members to...

Medscape Education

- PMLiVE

NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales

In England, more than six million people live with cardiovascular disease, costing the NHS around £7.4bn per year

- PMLiVE

Lexicon Pharma announces strong CV data for first-in-class sotagliflozin at the European Society of Cardiology’s annual meeting

The company will use data from the SOLOIST and SCORED trials as part of a new drug application later this year

- PMLiVE

CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug

The drug is recommended for use in adult patients who are already receiving statin treatment

- PMLiVE

Amarin shares tumble following Vascepa patent loss

Judgement invalidates six key patents on fish-oil derived med

- PMLiVE

Novo Nordisk gets MACE prevention claim for Ozempic in US

Key product for the future growth of Novo's diabetes franchise

- PMLiVE

Northsea Therapeutics raises $40m to develop fish oil NASH drug

Looking for mid-stage trial success in field littered with failures

- PMLiVE

FDA okays Amarin’s Vascepa for cardiovascular risk reduction

Drug is on course for blockbuster sales

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links